Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Existe información en español para pacientes y cuidadores, para acceder, haga clic sobre “Select” al lado de “I am a U.S. Patient / Caregiver”.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

CORLOPAM Highlights (fenoldopam mesylate injection, USP)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use CORLOPAM® safely and effectively. See full prescribing information for CORLOPAM®.

CORLOPAM® (fenoldopam mesylate) injection, for intravenous use
Initial U.S. Approval: 1997

INDICATIONS AND USAGE

Fenoldopam injection is a dopaminergic agonist indicated:

In adult patients for short term management of severe hypertension when rapid and reversible reduction of blood pressure is clinically indicated, including for malignant hypertension with deteriorating end-organ function (1.1).
In pediatric patients for short-term reduction in blood pressure (1.2).

DOSAGE AND ADMINISTRATION

Adults: Initiate dosing at 0.01 to 0.3 mcg/kg/min by continuous infusion. Dosing can be increased in increments of 0.05 to 0.1 mcg/kg/minute every 15 minutes or longer until target blood pressure is reached (2.1).
Dilute prior to administration (2.1, 2.2).
Pediatrics: Initiate dosing at 0.2 mcg/kg/minute by continuous infusion and titrate dose by 0.3 to 0.5 mcg/kg/min every 20-30 minutes to a maximum dose of 0.8 mcg/kg/minute (2.1, 2.2).

DOSAGE FORMS AND STRENGTHS

10 mg/mL solution in single-dose vial (3).

CONTRAINDICATIONS

None (4).

WARNINGS AND PRECAUTIONS

Fenoldopam causes a dose-related tachycardia, particularly with infusion rates above 0.1 mcg/kg/min (5.1).
Hypokalemia: Monitor potassium levels (5.2).
Increased intraocular pressure in patients with glaucoma or intraocular hypertension (5.3).
Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms in susceptible patients (5.4).

ADVERSE REACTIONS

The most common events (occurring in more than 5% of patients) reported associated with use are headache, cutaneous dilation (flushing), nausea, and hypotension (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Beta-blockers: Avoid concomitant use (7.1).

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 8/2021

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event